title: A phase II study of 4'-epirubicin in the treatment of poor-risk Kaposi's sarcoma and AIDS.
abstract: Twenty-six patients with poor-risk Kaposi's sarcoma and AIDS were treated with epirubicin 90 mg/m2 intravenously every 3 weeks. One patient achieved complete response and 10 achieved partial response (overall response rate 42.3%). The median time to treatment failure was 22 weeks. The dose-limiting toxicity was neutropenia.
authors.affiliation: Department of Medicine, Toronto General Hospital, Canada.
authors.forename: F A
authors.initials: FA
authors.lastname: Shepherd
authors.forename: R L
authors.initials: RL
authors.lastname: Burkes
authors.forename: K E
authors.initials: KE
authors.lastname: Paul
authors.forename: P E
authors.initials: PE
authors.lastname: Goss
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D009864:Ontario; D011446:Prospective Studies; D012074:Remission Induction; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D015996:Survival Rate
chemical_list: D015251:Epirubicin